Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/132725
Title: | Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer | Authors: | Arriola, Edurne de Castro, Javier Garcia-Campelo, Rosario Bernardez, Beatriz Bernabe, Reyes Bruna, Jordi Domine, Manuel Isla, Dolores Juan-Vidal, Oscar Lopez-Fernandez, Teresa Nadal, Ernest Rodriguez-Abreu, Delvys Vares, Maria Asensio, Ursula Garcia, Luis F. Felip, Enriqueta |
UNESCO Clasification: | 320713 Oncología | Keywords: | Open-Label Crizotinib Chemotherapy Multicenter Alectinib, et al |
Issue Date: | 2024 | Journal: | Clinical Drug Investigation | Abstract: | The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts. | URI: | http://hdl.handle.net/10553/132725 | ISSN: | 1173-2563 | DOI: | 10.1007/s40261-024-01379-7 | Source: | Clinical Drug Investigation [ISSN 1173-2563], (Julio 2024) |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.